Law enforcement officers are conducting searches in case of possible fraud during fundraising for the treatment of spinal ...

Living with SMA isn't just about survival, says columnist. There's also the emotional weight of preparing for the next crisis ...

Panelists discuss how spinal muscular atrophy (SMA) treatment will evolve over the next 5 years, likely incorporating ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

In a Phase I study, previously treated pediatric SMA patients exhibited reductions in a marker of neurodegeneration after salanersen treatment.

Based on these encouraging Phase 1 data, Biogen (NASDAQ:BIIB) is engaging with regulators to advance its investigational ...

A mother and daughter say they hope others don't have to go through the same fight to fund disability care as they did. Rae White is looking for further independence as she's about to turn 18. She has ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Biogen plans to advance an experimental treatment for the neuromuscular disease spinal muscular atrophy, or SMA, into registrational studies following encouraging results from an early-stage trial.

The cumulative data from the Phase 1 study indicate that salanersen has a generally well tolerated safety profile at both the 40 mg and 80 mg doses, with most adverse events (AEs) mild to moderate in ...

Aasmika Das, a baby from West Bengal, underwent a life-changing Zolgensma gene therapy for Spinal Muscular Atrophy Type 1, thanks to INR 8.41 crore raised by 5.29 lakh donors through Impact Guru. Her ...

BiogenBIIB said Wednesday its experimental treatment helped children with a devastating muscle-wasting disease even after they received an approved gene therapy from NovartisNVS.The company already ...